Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally.
Excellent balance sheet with reasonable growth potential.
Share Price & News
How has Veracyte's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: VCYT's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: VCYT underperformed the US Biotechs industry which returned -1.1% over the past year.
Return vs Market: VCYT underperformed the US Market which returned -13.6% over the past year.
Price Volatility Vs. Market
How volatile is Veracyte's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StIs Veracyte's (NASDAQ:VCYT) Share Price Gain Of 165% Well Earned?
1 month ago | Simply Wall StAre Veracyte, Inc. (NASDAQ:VCYT) Investors Paying Above The Intrinsic Value?
2 months ago | Simply Wall StVeracyte, Inc. (NASDAQ:VCYT) Is Expected To Breakeven
Is Veracyte undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: VCYT ($20.94) is trading below our estimate of fair value ($27.32)
Significantly Below Fair Value: VCYT is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: VCYT is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: VCYT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate VCYT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: VCYT is overvalued based on its PB Ratio (4.3x) compared to the US Biotechs industry average (2.7x).
How is Veracyte forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VCYT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: VCYT is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: VCYT's is expected to become profitable in the next 3 years.
Revenue vs Market: VCYT's revenue (15.1% per year) is forecast to grow faster than the US market (7.2% per year).
High Growth Revenue: VCYT's revenue (15.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: VCYT's Return on Equity is forecast to be low in 3 years time (2.4%).
How has Veracyte performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VCYT is currently unprofitable.
Growing Profit Margin: VCYT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: VCYT is unprofitable, but has reduced losses over the past 5 years at a rate of 15.2% per year.
Accelerating Growth: Unable to compare VCYT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VCYT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).
Return on Equity
High ROE: VCYT has a negative Return on Equity (-5.26%), as it is currently unprofitable.
How is Veracyte's financial position?
Financial Position Analysis
Short Term Liabilities: VCYT's short term assets ($187.7M) exceed its short term liabilities ($17.5M).
Long Term Liabilities: VCYT's short term assets ($187.7M) exceed its long term liabilities ($18.3M).
Debt to Equity History and Analysis
Debt Level: VCYT's debt to equity ratio (0.3%) is considered satisfactory.
Reducing Debt: VCYT's debt to equity ratio has reduced from 11.9% to 0.3% over the past 5 years.
Inventory Level: VCYT has a low level of unsold assets or inventory.
Debt Coverage by Assets: VCYT's debt is covered by short term assets (assets are 270.4x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VCYT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if VCYT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Veracyte's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VCYT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate VCYT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VCYT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VCYT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of VCYT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Bonnie Anderson (61yo)
Ms. Bonnie H. Anderson co-founded Veracyte, Inc. in 2008 and has served as its Chief Executive Officer and a Member of Board of Directors since February 2008. Ms. Anderson is Chairman of the Board at Verac ...
CEO Compensation Analysis
Compensation vs Market: Bonnie's total compensation ($USD2.83M) is about average for companies of similar size in the US market ($USD3.20M).
Compensation vs Earnings: Bonnie's compensation has increased whilst the company is unprofitable.
|CFO, COO & Secretary||3.33yrs||US$1.47m||0.12% $1.2m|
|Principal Accounting Officer||0.75yr||no data||0.037% $358.4k|
|Chief Scientific & Medical Officer||11.58yrs||no data||0.16% $1.6m|
|Chief Information Officer||3.08yrs||no data||no data|
|Vice President of Investor Relations and Corporate Communications||1.67yrs||no data||no data|
|Vice President of Marketing||2.25yrs||no data||no data|
|Vice President of Corporate & Business Development||1yr||no data||no data|
|Chief Commercial Officer||3.17yrs||no data||0.042% $410.8k|
|Senior Medical Director of Endocrinology||8yrs||no data||no data|
Experienced Management: VCYT's management team is considered experienced (3.1 years average tenure).
|Independent Director||7.33yrs||US$99.33k||0.027% $257.8k|
|Independent Director||13.25yrs||US$88.33k||0.080% $779.6k|
|Independent Director||12.17yrs||US$88.33k||0.050% $487.2k|
|Lead Independent Director||3.33yrs||US$112.33k||no data|
|Independent Director||4.42yrs||US$87.33k||no data|
|Independent Director||3.33yrs||US$97.33k||no data|
|Independent Director||5.25yrs||US$92.33k||no data|
|Member of Scientific Advisory Board||no data||no data||no data|
|Member of Clinical Advisory Board||no data||no data||no data|
Experienced Board: VCYT's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24.6%.
Veracyte, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Veracyte, Inc.
- Ticker: VCYT
- Exchange: NasdaqGM
- Founded: 2006
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$969.410m
- Shares outstanding: 49.74m
- Website: https://www.veracyte.com
Number of Employees
- Veracyte, Inc.
- 6000 Shoreline Court
- Suite 300
- South San Francisco
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|VCYT||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Oct 2013|
|12V||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Oct 2013|
Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery; Percepta Genomic Sequencing Classifier for lung cancer; Envisia Genomic Classifier that help physicians to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases without the need for surgery; and Prosigna Breast Cancer Prognostic Gene Signature Assay test for assessing risk of distant recurrence. It sells its products through product specialists, account managers, and medical science specialists. Veracyte, Inc. has a strategic collaboration with Johnson & Johnson Innovation and the Lung Cancer Initiative at Johnson & Johnson to advance the development and commercialization of novel diagnostic tests to detect lung cancer at its earliest stages; a research collaboration with Loxo Oncology for the development of therapies for patients with genetically defined cancers; and a collaboration with Johnson & Johnson Services, Inc. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/04 01:50|
|End of Day Share Price||2020/04/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.